Quick Takeaways
- ORBIMED ADVISORS LLC filed SCHEDULE 13G/A for X4 Pharmaceuticals, Inc Common Stock, par value $0.001 per share (XFOR).
- Disclosed ownership: 1.7%.
- Date of event: 30 Jun 2025.
ORBIMED ADVISORS LLC - 30 Jun 2025 SCHEDULE 13G/A Report for X4 Pharmaceuticals, Inc Common Stock, par value $0.001 per share (XFOR)
- Filing Manager
- ORBIMED ADVISORS LLC
- Reporting Manager
- ORBIMED ADVISORS LLC
- Symbol
- XFOR
- Shares outstanding
- 7,938,059 shares
- Disclosed Ownership
- 134,947 shares
- Ownership
- 1.7%
- Form type
- SCHEDULE 13G/A
- Filing time
- 14 Aug 2025, 17:53:08 UTC
- Date of event
- 30 Jun 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"ORBIMED ADVISORS LLC disclosed 1.7% ownership in X4 Pharmaceuticals, Inc Common Stock, par value $0.001 per share (XFOR) on 30 Jun 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 14 Aug 2025, 17:53.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 1.7% | 134,947 | 0 | 134,947 | /s/ Carl L. Gordon | Carl L. Gordon, Member |